Citi analyst Yigal Nochomovitz has issued strikingly bullish price targets for two biotech names, but the size of the projected gains also underscores the substantial risks embedded in both stories. The firm sees roughly 410% upside in Biomea Fusion and about 190% in Syndax Pharmaceuticals, yet the paths to those valuations are anything but certain.
Biomea's 410% call hinges on one obesity readout
Biomea is a clinical-stage company with no approved products. Its entire near-term thesis rests on BMF-650, an oral GLP-1 candidate for obesity. Citi rates the stock a Buy and has placed it on a 90-day catalyst watch ahead of Phase 1 data from the GLP-131 study, expected in the third quarter. Nochomovitz told TipRanks that BMF-650 could offer a "safer, but equally effective" oral alternative to existing GLP-1 therapies.
The potential payoff is amplified by Biomea's depressed valuation. The company's market cap assigns limited credit to BMF-650, so encouraging human data could trigger a sharp rerating. However, the risks are stark. BMF-650 is still in Phase 1, and while preclinical studies showed weight loss of up to roughly 15% in non-human primates, animal results often fail to translate to humans. Biomea also ended June with just $35.2 million in cash, equivalents, and restricted cash, giving it a runway only into the second quarter of 2027. That leaves financing and dilution as additional overhangs.
Syndax has sales, but Citi remains unusually bullish
Syndax presents a different profile. It already sells two FDA-approved cancer drugs, Revuforj and Niktimvo, which drove second-quarter revenue of $72.8 million, up 92% year over year. Revuforj contributed $54.7 million, while Niktimvo added $18.1 million in collaboration revenue. Still, the company posted a net loss of $49.4 million for the quarter.
Citi's thesis partly rests on patients staying on Revuforj for longer. Nochomovitz told TipRanks that growth should increasingly "compound through longer treatment duration rather than depend solely on new starts." He also expects a data-heavy second half, including readouts for revumenib and axatilimab, to strengthen the franchise.
Yet Citi's $57 target sits near the bullish edge of Wall Street. UBS analyst David Dai cut his target to $33 from $37 on Aug. 21 while retaining a Buy rating. JPMorgan reduced its target to $40 from $44, and H.C. Wainwright lowered its forecast to $38 from $40. That divergence highlights the uncertainty around Syndax's commercial execution and pipeline potential.
Huge upside also signals huge uncertainty
For Biomea, the main risks are clinical and financial. If BMF-650 produces compelling human weight-loss and tolerability data, the stock could rerate sharply because expectations are low. Disappointing results could weaken a central pillar of Citi's valuation argument while increasing pressure on Biomea's cash resources.
Syndax faces a different test: commercial execution. It must show Revuforj can expand through longer treatment duration, broader indications, and deeper market penetration while its pipeline produces data strong enough to support future growth. Citi believes that can happen, but lower targets from UBS, JPMorgan, and H.C. Wainwright show there is less agreement on how much investors should pay for that opportunity.
Investors weighing these names should consider the broader biotech landscape. For context, recent GLP-1 winners have seen limited upside after initial spikes, and broader market volatility can amplify biotech swings. Meanwhile, yield-driven selloffs have pressured high-valuation growth stocks, making risk assessment even more critical.
This article is for informational purposes only and does not constitute financial advice.
